

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:)
Claude AURIAULT et al.)
Application No.: 10/566,386) Group Art Unit: Unassigned
Filed: January 30, 2006) Examiner: Unassigned
National Stage of: PCT/IB2004/002374) Confirmation No. 5549
For: TRANSGENIC MICE HAVING A)
HUMAN MAJOR)
HISTOCOMPATIBILITY COMPLEX)
(MHC) PHENOTYPE,)
EXPERIMENTAL USES AND)
APPLICATIONS)

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

INFORMATION DISCLOSURE STATEMENT UNDER 37 C.F.R. § 1.97(b)

Pursuant to 37 C.F.R. §§ 1.56 and 1.97(b), Applicant brings to the attention of the Examiner the following information. This Information Disclosure Statement is being filed before the first Office Action on the merits.


Applicant wishes to apprise the Examiner of related, co-pending application Serial No. 10/882,241, filed July 2, 2004.

If there is any fee due in connection with the filing of this Statement, please charge the fee to our Deposit Account No. 06-0916.

Respectfully submitted,

FINNEGAN, HENDERSON, FARABOW,
GARRETT & DUNNER, L.L.P.

Dated: October 1, 2009

By: 

Kenneth J. Meyers
Reg. No. 25,146
Tel.: 202-408-4033
Fax: 202-408-4400
Email: ken.meyers@finnegan.com